You just read:

Health Canada approves CABOMETYX™ (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma

News provided by

Ipsen Biopharmaceuticals Canada Inc.

Nov 12, 2019, 08:00 ET